Allegan, Forest Laboratories and Ironwood Pharmaceuticals accused Sandoz of patent infringement in a recent suit to prevent Sandoz from bringing a generic version of Linzess to market.
The FDA approved Advanced Accelerator Applications’ Lutathera, a radioactive drug intended for the treatment of gastroenteropancreatic neuroendocrine tumors. This is the first time a radiopharmaceutical has been approved for the treatment of GEP-NETs.
Olympus added a new product to its EndoTherapy portfolio when it became the exclusive distributor of Intelligent Endoscopy’s SmartBand Multi-Band Ligation Kit.
Innovate Biopharmaceuticals completed its reverse merger with Monster Digital, entirely absorbing the company and becoming a publicly traded entity.
Exalenz Bioscience’s BreathID breath test platform can accurately detect clinically significant portal hypertension in non-alcoholic steatohepatitis patients with compensated advanced chronic liver disease.
The FDA approved Synergy Pharmaceuticals’ irritable bowel syndrome with constipation treatment Trulance.
More articles on gastroenterology:
Healthcare-related lobbying hits $555M in 2017 — 6 statistics on lobbying in healthcare
Advanced Medical Group joins National Spine & Pain Centers — 4 things to know
Preoperative opioid users more likely to abuse opioids after TKA — 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.